295 related articles for article (PubMed ID: 9582553)
21. Consequences of hyperhomocyst(e)inemia on vascular function in atherosclerotic monkeys.
Lentz SR; Malinow MR; Piegors DJ; Bhopatkar-Teredesai M; Faraci FM; Heistad DD
Arterioscler Thromb Vasc Biol; 1997 Nov; 17(11):2930-4. PubMed ID: 9409278
[TBL] [Abstract][Full Text] [Related]
22. Relation of plasma homocyst(e)ine to cerebral infarction and cerebral atherosclerosis.
Yoo JH; Chung CS; Kang SS
Stroke; 1998 Dec; 29(12):2478-83. PubMed ID: 9836754
[TBL] [Abstract][Full Text] [Related]
23. C2 monitoring in maintenance renal transplant recipients: is it worthwhile?
Midtvedt K; Fauchald P; Bergan S; Høieggen A; Hallan S; Svarstad E; Bergrem H; Eriksen BO; Pfeffer PF; Dalen I; Leivestad T
Transplantation; 2003 Oct; 76(8):1236-8. PubMed ID: 14578761
[TBL] [Abstract][Full Text] [Related]
24. Causes and consequences of hyperhomocyst(e)inemia.
Pietrzik K; Brönstrup A
Int J Vitam Nutr Res; 1997; 67(5):389-95. PubMed ID: 9350483
[TBL] [Abstract][Full Text] [Related]
25. Hyperhomocyst(e)inemia and endothelial dysfunction in IDDM.
Hofmann MA; Kohl B; Zumbach MS; Borcea V; Bierhaus A; Henkels M; Amiral J; Fiehn W; Ziegler R; Wahl P; Nawroth PP
Diabetes Care; 1997 Dec; 20(12):1880-6. PubMed ID: 9405911
[TBL] [Abstract][Full Text] [Related]
26. Hyperhomocyst(e)inemia and endothelial dysfunction in IDDM.
Hofmann MA; Kohl B; Zumbach MS; Borcea V; Bierhaus A; Henkels M; Amiral J; Schmidt AM; Fiehn W; Ziegler R; Wahl P; Nawroth PP
Diabetes Care; 1998 May; 21(5):841-8. PubMed ID: 9589252
[TBL] [Abstract][Full Text] [Related]
27. Hyperhomocyst(e)inemia is associated with carotid atherosclerosis.
Lupattelli G; Rufini S; Locati EH; Lombardini R; Ciuffetti G; Siepi D; Mannarino E
Angiology; 1999 Oct; 50(10):823-30. PubMed ID: 10535721
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results.
Krämer BK; Montagnino G; Del Castillo D; Margreiter R; Sperschneider H; Olbricht CJ; Krüger B; Ortuño J; Köhler H; Kunzendorf U; Stummvoll HK; Tabernero JM; Mühlbacher F; Rivero M; Arias M;
Nephrol Dial Transplant; 2005 May; 20(5):968-73. PubMed ID: 15741208
[TBL] [Abstract][Full Text] [Related]
29. Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence.
Eikelboom JW; Lonn E; Genest J; Hankey G; Yusuf S
Ann Intern Med; 1999 Sep; 131(5):363-75. PubMed ID: 10475890
[TBL] [Abstract][Full Text] [Related]
30. Hyperhomocyst(e)inemia and the increased risk of venous thromboembolism: more evidence from a case-control study.
Langman LJ; Ray JG; Evrovski J; Yeo E; Cole DE
Arch Intern Med; 2000 Apr; 160(7):961-4. PubMed ID: 10761961
[TBL] [Abstract][Full Text] [Related]
31. Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in monkeys with hyperhomocyst(e)inemia or hypercholesterolemia.
Böger RH; Bode-Böger SM; Sydow K; Heistad DD; Lentz SR
Arterioscler Thromb Vasc Biol; 2000 Jun; 20(6):1557-64. PubMed ID: 10845872
[TBL] [Abstract][Full Text] [Related]
32. ADMA and oxidative stress are responsible for endothelial dysfunction in hyperhomocyst(e)inemia: effects of L-arginine and B vitamins.
Sydow K; Schwedhelm E; Arakawa N; Bode-Böger SM; Tsikas D; Hornig B; Frölich JC; Böger RH
Cardiovasc Res; 2003 Jan; 57(1):244-52. PubMed ID: 12504835
[TBL] [Abstract][Full Text] [Related]
33. Hyperhomocyst(e)inemia, anti-estrogen antibodies and other risk factors for thrombosis in women on oral contraceptives.
Beaumont V; Malinow MR; Sexton G; Wilson D; Lemort N; Upson B; Beaumont JL
Atherosclerosis; 1992 Jun; 94(2-3):147-52. PubMed ID: 1632868
[TBL] [Abstract][Full Text] [Related]
34. Increasing plasma homocysteine during follow-up in heart transplant recipients: effects of folate and renal function.
Potena L; Grigioni F; Magnani G; Sorbello S; Sassi S; Marinucci L; Conti R; Carinci V; Leone O; Arpesella G; Coccheri S; Magelli C; Branzi A
Ital Heart J; 2000 May; 1(5):344-8. PubMed ID: 10832810
[TBL] [Abstract][Full Text] [Related]
35. Determinants of plasma homocyst(e)ine in patients with nephrotic syndrome.
Joven J; Arcelús R; Camps J; Ordóñez-Llanos J; Vilella E; González-Sastre F; Blanco-Vaca F
J Mol Med (Berl); 2000; 78(3):147-54. PubMed ID: 10868477
[TBL] [Abstract][Full Text] [Related]
36. Hyperhomocyst(e)inemia induces multiorgan damage.
Miller A; Mujumdar V; Shek E; Guillot J; Angelo M; Palmer L; Tyagi SC
Heart Vessels; 2000; 15(3):135-43. PubMed ID: 11289502
[TBL] [Abstract][Full Text] [Related]
37. Homocysteine and its determinants in nondialyzed chronic kidney disease patients.
Nerbass FB; Draibe SA; Feiten SF; Chiarello PG; Vannucchi H; Cuppari L
J Am Diet Assoc; 2006 Feb; 106(2):267-70. PubMed ID: 16442876
[TBL] [Abstract][Full Text] [Related]
38. Hyperhomocyst(e)inemia and Chlamydia pneumoniae IgG seropositivity in patients with coronary artery disease.
Stanger OH; Semmelrock HJ; Rehak P; Tiran B; Meinitzer A; Rigler B; Tiran A
Atherosclerosis; 2002 May; 162(1):157-62. PubMed ID: 11947909
[TBL] [Abstract][Full Text] [Related]
39. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ
Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
[TBL] [Abstract][Full Text] [Related]
40. Cardiovascular morbidity and endothelial dysfunction in chronic haemodialysis patients: is homocyst(e)ine the missing link?
Kunz K; Petitjean P; Lisri M; Chantrel F; Koehl C; Wiesel ML; Cazenave JP; Moulin B; Hannedouche TP
Nephrol Dial Transplant; 1999 Aug; 14(8):1934-42. PubMed ID: 10462274
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
